Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss.

structured approach to weight loss and metabolic health,” explains Serena Poon, C.N., CHC, CHN, certified nutritionist, celebrity chef, and wellness and longevity advisor. Meet the experts ...

Amid the soaring use of glucagon-like peptide-1 (GLP-1) drugs for intentional weight loss, a vastly different movement appears to be gaining traction in health care: Many clinicians are pushing for a ...

The researchers found that the 5-year risks for revision among 3691 participants was 5.6% for patients in the weight gain or stable weight group compared with 3.9% in patient with greater than 10% ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.